Our study uncovered a striking, context‐dependent functional switch for DCAF12, which exhibits oncogenic activity in mammals despite its tumor‐suppressive role in Drosophila, highlighting the therapeutic potential of targeting the DCAF12‐TRiC/CCT axis. This evidence concerns the gene DCAF12 and neoplasm.